Presentation is loading. Please wait.

Presentation is loading. Please wait.

Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival  Brian L. McClune, Kwang Woo Ahn, Hai-Lin.

Published byJean-Pascal Charpentier Modified over 5 years ago

Similar presentations

Presentation on theme: "Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival  Brian L. McClune, Kwang Woo Ahn, Hai-Lin."— Presentation transcript:

1 Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival  Brian L. McClune, Kwang Woo Ahn, Hai-Lin Wang, Joseph H. Antin, Andrew S. Artz, Jean-Yves Cahn, Abhinav Deol, César O. Freytes, Mehdi Hamadani, Leona A. Holmberg, Madan H. Jagasia, Ann A. Jakubowski, Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Alan M. Miller, Richard Olsson, Tanya L. Pedersen, Joseph Pidala, Michael A. Pulsipher, Jacob M. Rowe, Wael Saber, Koen W. van Besien, Edmund K. Waller, Mahmoud D. Aljurf, Görgun Akpek, Ulrike Bacher, Nelson J. Chao, Yi-Bin Chen, Brenda W. Cooper, Jason Dehn, Marcos J. de Lima, Jack W. Hsu, Ian D. Lewis, David I. Marks, Joseph McGuirk, Mitchell S. Cairo, Harry C. Schouten, Jeffrey Szer, Muthalagu Ramanathan, Bipin N. Savani, Matthew Seftel, Gérard Socie, Ravi Vij, Erica D. Warlick, Daniel J. Weisdorf  Biology of Blood and Marrow Transplantation  Volume 20, Issue 7, Pages (July 2014) DOI: /j.bbmt Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Three-year relapse and PFS based on histology. (A) Progression/relapse, aggressive NHL. (B) PFS, aggressive NHL. (C) Progression/relapse, indolent NHL. (D) PFS, indolent NHL. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Three-year PFS (A) and OS (B) after allogeneic HCT for NHL.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival  Brian L. McClune, Kwang Woo Ahn, Hai-Lin."

Similar presentations

Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes  Lori.

Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes  Lori.
Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation  Karen Ballen, Kwang Woo Ahn, Min Chen, Hisham.

Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation  Karen Ballen, Kwang Woo Ahn, Min Chen, Hisham.
Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S.

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S.
Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma  Baldeep Wirk, Timothy S. Fenske,

Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma  Baldeep Wirk, Timothy S. Fenske,
Amifostine Reduces High-Dose Melphalan Induced Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplant (HCT) for Plasma Cell Myeloma  Vinita.

Amifostine Reduces High-Dose Melphalan Induced Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplant (HCT) for Plasma Cell Myeloma  Vinita.
Center for International Blood and Marrow Transplant Research Chronic Graft-versus- Host Disease Risk Score Predicts Mortality in an Independent Validation.

Center for International Blood and Marrow Transplant Research Chronic Graft-versus- Host Disease Risk Score Predicts Mortality in an Independent Validation.
Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation 

Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation 
Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic.

Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic.
Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.

Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.
Nishitha M. Reddy, Olalekan Oluwole, John P. Greer, Brian G

Nishitha M. Reddy, Olalekan Oluwole, John P. Greer, Brian G
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular.

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular.
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma  Robert F. Cornell, Anita D'Souza, Adetola.

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma  Robert F. Cornell, Anita D'Souza, Adetola.
Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive.

Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive.
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant.

Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant.
Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis  Emma C. Scott, Parameswaran Hari, Manish Sharma,

Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis  Emma C. Scott, Parameswaran Hari, Manish Sharma,
Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia  Karen K. Ballen, Ann E. Woolfrey, Xiaochun.

Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia  Karen K. Ballen, Ann E. Woolfrey, Xiaochun.
Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes  Lori.

Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes  Lori.
Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome  Philippe Armand,

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome  Philippe Armand,
HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced- Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from.

HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced- Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from.
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia  Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani,

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia  Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani,

Similar presentations

Ads by Google